JPH02500597A - Hiv‐1関連ポリペプチド類、診断システム類及びアッセイ方法 - Google Patents
Hiv‐1関連ポリペプチド類、診断システム類及びアッセイ方法Info
- Publication number
- JPH02500597A JPH02500597A JP50730988A JP50730988A JPH02500597A JP H02500597 A JPH02500597 A JP H02500597A JP 50730988 A JP50730988 A JP 50730988A JP 50730988 A JP50730988 A JP 50730988A JP H02500597 A JPH02500597 A JP H02500597A
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- antibodies
- polypeptides
- hiv
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 200
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 189
- 229920001184 polypeptide Polymers 0.000 title claims description 180
- 238000003556 assay Methods 0.000 title claims description 31
- 241000713772 Human immunodeficiency virus 1 Species 0.000 title claims description 26
- 239000000203 mixture Substances 0.000 claims description 62
- 125000000539 amino acid group Chemical group 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 32
- 230000008105 immune reaction Effects 0.000 claims description 31
- 239000007787 solid Substances 0.000 claims description 30
- 239000007795 chemical reaction product Substances 0.000 claims description 27
- 229960000310 isoleucine Drugs 0.000 claims description 24
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 23
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 23
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 21
- 229930182817 methionine Natural products 0.000 claims description 20
- 210000001124 body fluid Anatomy 0.000 claims description 17
- 239000010839 body fluid Substances 0.000 claims description 17
- 239000000758 substrate Substances 0.000 claims description 16
- 230000009870 specific binding Effects 0.000 claims description 14
- 238000009739 binding Methods 0.000 claims description 10
- 238000002372 labelling Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000011541 reaction mixture Substances 0.000 claims description 10
- 230000027455 binding Effects 0.000 claims description 9
- 108060003951 Immunoglobulin Proteins 0.000 claims description 8
- 238000004166 bioassay Methods 0.000 claims description 8
- 102000018358 immunoglobulin Human genes 0.000 claims description 8
- 230000036046 immunoreaction Effects 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- 230000036436 anti-hiv Effects 0.000 claims description 7
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 claims description 3
- 229940000425 combination drug Drugs 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 description 26
- 210000002966 serum Anatomy 0.000 description 23
- 239000000523 sample Substances 0.000 description 21
- 239000003153 chemical reaction reagent Substances 0.000 description 18
- 208000030507 AIDS Diseases 0.000 description 16
- 101710112672 Probable tape measure protein Proteins 0.000 description 14
- 101710204224 Tape measure protein Proteins 0.000 description 14
- 239000011230 binding agent Substances 0.000 description 14
- 229960004452 methionine Drugs 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 239000000427 antigen Substances 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 239000002054 inoculum Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 241000124008 Mammalia Species 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 101710132601 Capsid protein Proteins 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000007790 solid phase Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 229960003136 leucine Drugs 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- -1 7: l-me (J Inorganic materials 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 102100034349 Integrase Human genes 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 229960002885 histidine Drugs 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- 239000007771 core particle Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000010185 immunofluorescence analysis Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001459 mortal effect Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 108700000434 Cannabis sativa edestin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 1
- 229930182847 D-glutamic acid Natural products 0.000 description 1
- 101100411708 Danio rerio rarga gene Proteins 0.000 description 1
- 241001364343 Derops Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 108700010908 HIV-1 proteins Proteins 0.000 description 1
- 241000748653 Invertebrate iridescent virus 1 Species 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101000582398 Staphylococcus aureus Replication initiation protein Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010015780 Viral Core Proteins Proteins 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 108010031071 cholera toxoid Proteins 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- BRHPBVXVOVMTIQ-ZLELNMGESA-N l-leucine l-leucine Chemical compound CC(C)C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O BRHPBVXVOVMTIQ-ZLELNMGESA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000379 polypropylene carbonate Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 238000001814 protein method Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- MSTPNDZQVGSTET-UHFFFAOYSA-M sodium;2-anilino-6-sulfanylidene-1h-1,3,5-triazine-4-thiolate Chemical compound [Na+].N1C(=S)N=C([S-])N=C1NC1=CC=CC=C1 MSTPNDZQVGSTET-UHFFFAOYSA-M 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000010648 susceptibility to HIV infection Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.以下の式: LGZWGCSGKHIC, (式中、Zはイソロイシン若しくはメチオニンのいずれかを示す) で表わされるアミノ酸残基配列を有する12個のアミノ酸残基類を必須成分とし て成るポリペプチド。 2.少なくとも2個のポリペプチド類の混合物を含む組成物であって、第1の該 ポリペプチド類は以下の式:LGZWGCSGKHIC (式中、Zはイソロイシン若しくはメチオニンのいずれかを示す) で表わされる配列を有する12個のアミノ酸残基を必須成分として成り,かつ第 2の該ポリペプチド類はヒト免疫不全ウィルスによって誘導される抗体類と免疫 反応することができるものであることを特徴とする組成物。 3.第2の当該ポリペプチド類か以下の式から成る群:LGLWGCSGKLI C LGIWGCSGKLIC,及び NSWGCAFRGVC; から選ばれた式で表わされるアミノ酸残基配列を有する、請求の範囲2に記載の 組成物。 体液試料中の抗HIV−1抗体類の存在をアッセイする方法であって、以下のa )〜c)の段階、すなわち:4.a)以下の式: LGZWGCSGKHIC (式中、Zはイソロイシン若しくはメチオニンのいずれかを示す) で表わされる配列を有する12個のアミノ酸残基類を必須成分として成るポリペ プチドと、体液試料を混合することにより免疫反応混合物を形成すること; b)該試料中に存在するいずれの抗HIV−1抗体類もが当該ポリペプチドと免 疫反応してポリペプチド含有性免疫反応産物を形成するのに十分な時間にわたり 、生物学的アッセイ条件下に 当該免疫反応混合物を維持すること;及びc)形 成されたいずれのポリペプチド含有性免疫反応産物の存在をアッセイすること、 及びそれにより当該試料中のいずれの抗HIV−1抗体類の存在をもアッセイす ること、を含む該アッセイ方法。 5.該ポリペプチド含有性免疫反応産物が段階(c)によるアッセイのためにさ らに以下の段階によって調製される、請求の範囲4に記載の方法: (i)該免疫反応産物中に存在するいかなるヒト免疫グロブリンとも結合しうる ラベルされた抗体分子類を当該ポリペプチド含有性免疫反応産物と混合すること により、ラベル化反応混合物を形成すること、及び (ii)ラベルされた当該抗体類がポリペプチド含有性免疫反応産物として存在 するいずれの抗HIV−1抗体類とも免疫反応してラベル化複合体を形成するの に十分な時間にわたり生物学的アッセイ条件下で、(i)で形成された該ラベル 化反応混合物を維持すること。 6.段階(a)の該混合に先立ち該ポリペプチドを固体基質に付着させる、請求 の範囲5に記載の方法。 7.体液試料中の抗HIV−1抗体類の存在をアッセイする方法であって、以下 の(a)〜(c)の段階、すなわち:a)体液試料を、少なくとも2つのポリペ プチドの混合物を含む組成物であって、第1の核ポリペプチド類は以下の式:L GZWGCSGKHIC (式中、Zはイソロイシン若しくはメチオニンを示す)で表わされる配列を有す る12個のアミノ酸残基を必須成分として成り、かつ第2の該ポリペプチド類が 以下の式から成る群: LGLWGCSGKLIC LGIWGCSGKLIC,及び NSWGCAFROC; から選ばれた式で表わされるものであることを特徴とする該組成物と混合するこ とにより免疫反応混合物を形成すること;b)該試料中に存在するいずれの抗H IV抗体類もが当該ポリペプチドと免疫反応してポリペプチド含有性免疫反応産 物を形成するのに十分な時間にわたり、生物学的アッセイ条件下に当該免疫反応 混合物を維持すること;及びc)形成されたいずれのポリペプチド含有性免疫反 応産物の存在をアッセイすること、及びそれにより当該試料中のいずれの抗HI V抗体類の存在をもアッセイすること、を含む該アッセイ方法。 8.該ポリペプチド含有性免疫反応産物が段階(c)によるアッセイのためにさ らに以下の段階によって調製される、請求の範囲7に記載の方法: (i)免疫反応産物として存在するいかなるヒト免疫グロブリンとも結合しうる ラベルされた抗体分子類を当該ポリペプチド含有性免疫反応産物と混合すること により、ラベル化反応混合物を形成すること、及び (ii)ラベルされた該抗体類がポリペプチド含有性免疫反応産物として存在す るいずれの抗HIV抗体類とも免疫反応してラベル化複合体を形成するのに十分 な時間にわたり生物学的アッセイ条件下で、(i)で形成された該ラベル化反応 混合物を維持すること。 9.段階(a)の該混合に先立ち該ポリペプチドを固体基質に付着させる、請求 の範囲7に記載の方法。 10.体液試料中の抗HIV−1抗体類の存在をアッセイするキット型診断シス テムであって以下の式: LGZWGCSGXHIC (式中、Zはイソロイシン若しくはメチオニンを示す)で表わされるアミノ酸残 基配列を有するポリペプチドを含有するパッケージを含む診断システム。 11.体液試料中の抗HIV抗体類の存在をアッセイするキット型診断システム であって、少なくとも2個のポリペプチド類を含有するパッケージを含み、第1 の該ポリペプチド類か以下の式:LGZWGCSGKHIC (式中、Zはイソロイシン若しくはメチオニンを示す)で表わされるアミノ酸残 基配列を有し、第2の該ポリペプチド類かヒト免疫不全ウィルスによって誘導さ れる抗体類と免疫反応しうるものであることを特徴とする該診断システム。 12.該第2のポリペプチド類が以下の式から成る群:LGLWGCSGKLI C, LGIWGCSGKLIC,及び NSWGCAFRQVC; から選ばれた式で表わされるアミノ酸残基配列を有する請求の範囲11に記載の 診断システム。 13.該第1及び第2のポリペプチド類が混合されている、請求の範囲11に記 載の診断システム。 14.ポリペプチド含有性免疫反応産物の存在を表示するラベルされた特異的結 合剤を別個のパッケージ中にさらに含有する、請求の範囲11に記載の診断シス テム。 15.該ポリペプチドが固体基質に付着した、請求の範囲11に記載の診断シス テム。 16.(a)以下の式: LGZWGCSGKHIC (式中、Zはイソロイシン若しくはメチオニンを示す)で表わされるアミノ酸残 基配列を有するポリペプチドが有効に付着している固体基質を含む第1の固形担 体;及び(b)以下の式からなる群、 LGLWGCSGKLIC, LGIWGCSGKIC,及び NSWGCAFROVC, から選ばれた式で表わされるアミノ酸残基配列を有するポリペプチドが有効に付 着している固体基質を含む第2の固形担体: を含むキット型診断システム。 17.(a)少なくとも2個のポリペプチド類の混合物が有効に付着している固 体基質を含む第1の固形担体であって、第1の該ポリペプチド類が以下の式: LGZWGCSGKHIC (式中、Zはイソロイシン若しくは20チオニンを示す)で表わされるアミノ酸 残基配列を有し、第2の該ポリペプチド類か以下の式から成る群: LGLWGCSGKLIC,及び LGIWGCSGKLIC, から選ばれた式で表わされるアミノ酸残基配列を有する第1の固形担体;及び (b)以下の式: NSWGCAFROVC, で表わされるアミノ酸残基配列を有するポリペプチドが有効に付着している固体 基質を含む第2の固形担体:を含むキット型診断システム。 HIV−1関連ポリペプチド類、診断システム類及びアッセイ方法
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8806787A | 1987-08-21 | 1987-08-21 | |
US088,067 | 1987-08-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH02500597A true JPH02500597A (ja) | 1990-03-01 |
JP2902658B2 JP2902658B2 (ja) | 1999-06-07 |
Family
ID=22209204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP63507309A Expired - Lifetime JP2902658B2 (ja) | 1987-08-21 | 1988-08-19 | Hiv‐1関連ポリペプチド類、診断システム類及びアッセイ方法 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0329761B1 (ja) |
JP (1) | JP2902658B2 (ja) |
AU (1) | AU614543B2 (ja) |
DE (1) | DE3886032T2 (ja) |
DK (1) | DK173905B1 (ja) |
FI (1) | FI95274C (ja) |
NO (1) | NO177536C (ja) |
WO (1) | WO1989001494A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8828098D0 (en) * | 1988-12-01 | 1989-01-05 | Wellcome Found | Peptides |
US6248574B1 (en) | 1989-12-13 | 2001-06-19 | Avigdor Shaffermann | Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides |
FR2732346B1 (fr) * | 1995-03-27 | 1997-05-30 | Centre Nat Rech Scient | Proteines mutees, codees par un gene env mute de lentivirus, fragments peptidiques inclus dans lesdites proteines, vecteurs d'expression exprimant lesdites proteines mutees et leurs applications |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4629783A (en) * | 1985-04-29 | 1986-12-16 | Genetic Systems Corporation | Synthetic antigen for the detection of AIDS-related disease |
DE3887053T4 (de) * | 1987-04-16 | 1994-09-08 | Johnson & Johnson | Stlv-iii-verwandte polypeptide, diagnosesysteme und testmethoden. |
-
1988
- 1988-08-19 EP EP19880907953 patent/EP0329761B1/en not_active Expired - Lifetime
- 1988-08-19 WO PCT/US1988/002870 patent/WO1989001494A1/en active IP Right Grant
- 1988-08-19 JP JP63507309A patent/JP2902658B2/ja not_active Expired - Lifetime
- 1988-08-19 AU AU23021/88A patent/AU614543B2/en not_active Expired
- 1988-08-19 DE DE3886032T patent/DE3886032T2/de not_active Expired - Lifetime
-
1989
- 1989-04-20 NO NO891635A patent/NO177536C/no not_active IP Right Cessation
- 1989-04-20 FI FI891898A patent/FI95274C/fi not_active IP Right Cessation
- 1989-04-20 DK DK198901931A patent/DK173905B1/da not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
THE JOURNAL OF INFECTIOUS DISEASES=1987 * |
Also Published As
Publication number | Publication date |
---|---|
EP0329761A1 (en) | 1989-08-30 |
NO891635L (no) | 1989-06-20 |
DE3886032T2 (de) | 1994-06-16 |
EP0329761B1 (en) | 1993-12-01 |
AU614543B2 (en) | 1991-09-05 |
DK173905B1 (da) | 2002-02-11 |
NO891635D0 (no) | 1989-04-20 |
FI891898A0 (fi) | 1989-04-20 |
DK193189D0 (da) | 1989-04-20 |
NO177536C (no) | 1995-10-04 |
DK193189A (da) | 1989-04-20 |
EP0329761A4 (en) | 1990-09-26 |
FI95274B (fi) | 1995-09-29 |
JP2902658B2 (ja) | 1999-06-07 |
WO1989001494A1 (en) | 1989-02-23 |
DE3886032D1 (de) | 1994-01-13 |
AU2302188A (en) | 1989-03-09 |
FI95274C (fi) | 1996-01-10 |
NO177536B (no) | 1995-06-26 |
FI891898A (fi) | 1989-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1340735C (en) | Htlv-iii envelope peptides | |
US5017687A (en) | Peptides for the detection of HTLV-1 infection | |
EP0891982B1 (en) | HIV peptides | |
AU606928B2 (en) | Synthetic peptide antigens for the detection of hiv-1 infection | |
JPS63221247A (ja) | エイズ関連症の検出用合成抗原 | |
EP0247557B1 (en) | HTLV-III(LAV) Envelope peptides | |
JPH07502484A (ja) | 哺乳動物免疫不全ウイルスの検出 | |
JP2777160B2 (ja) | Stlv‐3関連ポリペプチド、診断系および検定法 | |
JPH03504165A (ja) | Htlv‐1抗体に対する免疫反応性を有する合成ペプチド組成物 | |
FI111731B (fi) | Immuunikatoviruksen endonukleaasiproteiinista johdetut polypeptidit ja niiden käyttö diagnostiikassa | |
JPH02500597A (ja) | Hiv‐1関連ポリペプチド類、診断システム類及びアッセイ方法 | |
US5283320A (en) | Peptides for HTLV-2 infection diagnosis of, therapy for, vaccination against, for distinguishing between HTLV-1 and HTLV-2 infections and antibodies derived therefrom | |
CA1338001C (en) | Synthetic peptide antigens for the detection of htlv-1 infection | |
JPH0215098A (ja) | Hiv−1感染検出用合成ペプチド杭原、その組成物およびその使用方法 | |
Virovahl | Vahlne et al. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080319 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090319 Year of fee payment: 10 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090319 Year of fee payment: 10 |